Merck nears $1.3 bln takeover of Eyebiotech- WSJ

Investing.com-- Merck&Company Inc (NYSE: MRK) is close to entering a $1.3 billion deal to buy Eyebiotech, granting the pharmaceutical giant entry into the rapidly growing eyecare market, the Wall Street Journal reported on Tuesday.

The drugmaker is expected to pay $1.3 billion in cash for the ophthalmology firm, and could pay up to $1.7 billion in additional milestone payments, the WSJ reported, citing people with knowledge of the matter.

You May Also Be Interested In

• BASF proposes takeover of German chemical rival Evonik, Financial Times reports
• Merck's remigromig meets primary endpoint in DME phase 2b/3 trial
• Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn